**Patient-centred development and validation of the Patient-Reported Impact of Dermatological Diseases (PRIDD) measure**

Rachael Pattinson, Nirohshah Trialonis-Suthakharan, Jennifer Austin, Allison FitzGerald, Matthias Augustin and Chris Bundy

**Background:** Dermatological conditions are highly prevalent worldwide and significantly impact upon quality of life. The psychological and social impacts include the stigma of living with a visible condition, symptoms including pain and itch, self-management, depression, anxiety, stigma, and social isolation.

Existing patient-reported outcome measures (PROMs) are not theory-informed and do not comprehensively capture the impact of dermatological diseases on patients’ lives and therefore underestimate patient burden. The Global Research on the Impact of Dermatological Diseases (GRIDD) project is developing a new measure of the impact of dermatological conditions on patients’ lives called PRIDD (Patient-Reported Impact of Dermatological Diseases).

**Methods:** GRIDD is a mixed methods study consisting of five phases: 1) COSMIN systematic review. 2) Qualitative interview study developing the conceptual framework of impact and generating items. 3) Delphi study eliciting consensus from patients on which impact items to prioritise for inclusion in PRIDD. 4) Cognitive interview study evaluating content validity, acceptability, and feasibility. 5) Psychometric testing.

**Results:** 2,221 people representing 90 conditions from 61 countries participated. None of the 36 PROMs evaluated in the systematic review were recommended for use as the ‘gold standard’. The conceptual framework depicted impact as a multifaceted construct involving physical, life responsibilities, psychological and social impacts. The Delphi study reduced the item pool of 263 to a 27-item draft of PRIDD. Cognitive interviews produced a 26-item version of PRIDD with evidence of content validity, feasibility, and acceptability from patients. A confirmatory factor analysis refined the conceptual framework. PRIDD fits the Rasch model. Testing of further measurement properties is underway.

**Conclusions and implications:** PRIDD has been developed in close collaboration with patients and meets the gold-standard COSMIN criteria. PRIDD will greatly enhance patient perspectives by providing quantifiable patient impact data for better decision-making at the individual, national and global levels, with higher prioritisation of dermatological conditions.